EC Number   |
Application |
Reference |
|---|
    3.5.1.23 | analysis |
development of a method for the specific visualization of catalytically active acid ceramidase in intracellular compartments is crucial for diagnosis and follow-up of therapeutic strategies in diseases linked to altered enzyme activity |
753979 |
| 3.5.1.23 | drug development |
development of small molecule drugs, that inhibit AC enzyme activity, is a promising approach for improving standard cancer therapy and patient's clinical outcomes |
711949 |
| 3.5.1.23 | medicine |
because of its central role in the ceramide metabolism, the enzyme may offer a novel molecular target in disorders with dysfunctional ceramide-mediated signaling |
733093 |
| 3.5.1.23 | medicine |
CDase from Pseudomonas aeruginosa may be a virulence factor in infections, may be involved in the ceramide deficiency in the horny layer of the epidermis of patients with atopic dermatitis suffering from bacterial infections |
657260 |
| 3.5.1.23 | medicine |
downregulation of acid ceramidase increases sensitivity to radiation |
700316 |
| 3.5.1.23 | medicine |
Farber disease is diagnosed by the demonstration of reduced acid ceramidase activity, abnormally high ceramide levels in cultured cells, biopsy samples or urine, and the presence of Farber bodies, comma-shaped curvilinear tubular structures. The enzyme is likely to continue to be a target for new drug development in cancer and other disorders |
685316 |
| 3.5.1.23 | medicine |
in human prostate tissues, acid ceramidase and cathepsin B overexpression are strongly associated and may relate to poor outcome |
719608 |
| 3.5.1.23 | medicine |
inhibition of acid ceramidase is useful in cancer treatment |
719536 |
| 3.5.1.23 | medicine |
patients with the lipid storage disorder, the Farber disease, have a marked AC deficiency |
656154 |
| 3.5.1.23 | pharmacology |
enzyme inhibition may be beneficial in cancer therapy |
752968 |
